MD, PhD, Associate Chief Physician, Department of Gastrointestinal Oncology, Peking University Cancer Hospital. He once concurrently served as the Xizang‑aid Director of the Oncology Department of Lhasa People's Hospital. He has long been engaged in standardized diagnosis and treatment, clinical research and multidisciplinary comprehensive management of digestive system tumors including gastric cancer, biliary tract cancer, pancreatic cancer, liver cancer and colorectal cancer. He has accumulated extensive experience particularly in molecular precision diagnosis and treatment of hepatobiliary and pancreatic tumors, optimization of AI‑enabled therapeutic strategies, and individualized tumor treatment models in high‑altitude regions. He has undertaken internal innovation projects of Peking University Cancer Hospital, etc. Representative achievements include: 1. Large‑language‑model‑based research on diagnosis and treatment prediction for gastric cancer, biliary tract cancer and pancreatic cancer (Innovation Med, 2023); 2. Research on multimodal precise prediction model for HER2‑positive gastric cancer (Signal Transduct Target Ther, 2024); 3. Research on large language models in digestive tract tumor management (Medicine Plus, 2024); 4. Ongoing research on survival patterns and treatment patterns of gastric cancer patients in high‑altitude regions; 5. Clinical research and real‑world practice on advances in CLDN18.2, KRAS G12C/G12D targeted therapies and ADC agents. He has received honors such as Outstanding Individual for Xizang‑aid Work of Peking University and Outstanding Xizang‑aid Individual of Lhasa People's Hospital. He is committed to advancing precision medicine for hepatobiliary and pancreatic tumors, AI‑assisted clinical decision‑making, and the development of tumor prevention and treatment systems in high‑altitude regions.